Article in Proceedings of the National Academy of Sciences of the United States of America, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
17 authors.
Kang-Liang Lou *Fujian Key Laboratory of Precision Diagnosis and Treatment in Breast Cancer and Xiamen Key Laboratory of Endocrine-Related Cancer Precision Medicine, School of Medicine, Xiamen University, Xiamen, Fujian 361102, China.ORCID 0000-0001-5465-8244
Jing-Wen Bai *The Breast Center and the Cancer Institute of Yunnan Cancer Hospital, Yunnan Key Laboratory of Molecular Imaging in Oncology, The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Peking University Cancer Hospital Yunnan, Kunming, Yunnan 650118, China.ORCID 0000-0002-2107-2746
Hong-Tan Liu *Ministry of Education Key Laboratory of Spectrochemical Analysis and Instrumentation, Department of Chemistry, College of Chemistry and Chemical Engineering, Xiamen University, Xiamen, Fujian 361005, China.
Lin-Ling LinFujian Key Laboratory of Precision Diagnosis and Treatment in Breast Cancer and Xiamen Key Laboratory of Endocrine-Related Cancer Precision Medicine, School of Medicine, Xiamen University, Xiamen, Fujian 361102, China.ORCID 0009-0002-8761-0487
Cheng-Xi LiFujian Key Laboratory of Precision Diagnosis and Treatment in Breast Cancer and Xiamen Key Laboratory of Endocrine-Related Cancer Precision Medicine, School of Medicine, Xiamen University, Xiamen, Fujian 361102, China.ORCID 0009-0001-0448-4167
Yi-Yang GaoFujian Key Laboratory of Precision Diagnosis and Treatment in Breast Cancer and Xiamen Key Laboratory of Endocrine-Related Cancer Precision Medicine, School of Medicine, Xiamen University, Xiamen, Fujian 361102, China.
Sheng-Jie LinFujian Key Laboratory of Precision Diagnosis and Treatment in Breast Cancer and Xiamen Key Laboratory of Endocrine-Related Cancer Precision Medicine, School of Medicine, Xiamen University, Xiamen, Fujian 361102, China.ORCID 0009-0009-6149-7288
Yi-Fei PeiFujian Key Laboratory of Precision Diagnosis and Treatment in Breast Cancer and Xiamen Key Laboratory of Endocrine-Related Cancer Precision Medicine, School of Medicine, Xiamen University, Xiamen, Fujian 361102, China.ORCID 0009-0002-1403-7704
Xiao-Long WeiDepartment of Pathology, Cancer Hospital of Shantou University Medical College, Shantou, Guangdong 515041, China.
Yi-Xin ChenFujian Key Laboratory of Precision Diagnosis and Treatment in Breast Cancer and Xiamen Key Laboratory of Endocrine-Related Cancer Precision Medicine, School of Medicine, Xiamen University, Xiamen, Fujian 361102, China.ORCID 0009-0009-6367-1200
Yi-Yin TangThe Breast Center and the Cancer Institute of Yunnan Cancer Hospital, Yunnan Key Laboratory of Molecular Imaging in Oncology, The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Peking University Cancer Hospital Yunnan, Kunming, Yunnan 650118, China.
Hong-Yu ChenFujian Key Laboratory of Precision Diagnosis and Treatment in Breast Cancer and Xiamen Key Laboratory of Endocrine-Related Cancer Precision Medicine, School of Medicine, Xiamen University, Xiamen, Fujian 361102, China.ORCID 0000-0002-8345-6091
Zhi-Yao LiDepartment of Medical Ultrasound, The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Peking University Cancer Hospital Yunnan, Kunming, Yunnan 650118, China.
Rong GuoThe Breast Center and the Cancer Institute of Yunnan Cancer Hospital, Yunnan Key Laboratory of Molecular Imaging in Oncology, The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Peking University Cancer Hospital Yunnan, Kunming, Yunnan 650118, China.ORCID 0000-0002-7342-3237
Shi-Cong TangThe Breast Center and the Cancer Institute of Yunnan Cancer Hospital, Yunnan Key Laboratory of Molecular Imaging in Oncology, The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Peking University Cancer Hospital Yunnan, Kunming, Yunnan 650118, China.ORCID 0000-0002-0666-5172
Chuan-Liu WuMinistry of Education Key Laboratory of Spectrochemical Analysis and Instrumentation, Department of Chemistry, College of Chemistry and Chemical Engineering, Xiamen University, Xiamen, Fujian 361005, China.ORCID 0000-0003-2946-7299
Guo-Jun ZhangThe Breast Center and the Cancer Institute of Yunnan Cancer Hospital, Yunnan Key Laboratory of Molecular Imaging in Oncology, The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Peking University Cancer Hospital Yunnan, Kunming, Yunnan 650118, China.ORCID 0000-0001-5182-5887
Funding
Horizontal project funding from the Third Affiliated Hospital of Kunming Medical University 20233160A0866Horizontal project funding from the Third Affiliated Hospital of Kunming Medical University 20243160A0511International Joint Laboratory on Cancer Molecular Imaging of Yunnan 202503AP140032Jie Tian Specialist Workstation in Yunnan 202505AF350067Key Research and Development Program for Social Development of Yunnan Science and Technology Department 202403AC100014MOST | National Natural Science Foundation of China (NSFC) 22174119MOST | National Natural Science Foundation of China (NSFC) 22474119MOST | National Natural Science Foundation of China (NSFC) 32171363MOST | National Natural Science Foundation of China (NSFC) 82560355Research Project of Yunnan Clinical Medical Center 2024YNLCYXZX0418
6 · The paper itself
Abstract
In early breast cancer surgery (EBC), free margins significantly decrease local recurrence in breast-conserving surgery (BCS), while metastatic status of sentinel lymph node (SLN) impacts axillary management. However, intraoperative visualization of margins and metastatic SLNs (mSLNs) remains challenging. Here, we report a second-window near-infrared (NIR-II) fluorescence probe by conjugating ICG to TROP2-targeting cyclic peptide (TTP-ICG). Our results showed that TTP-ICG specifically binds to TROP2-expressing cells in vitro and identifies TROP2-positive tumors in vivo. In addition, TTP-ICG enabled efficient intraoperative evaluation of surgical margins and visualization of mSLNs at a submillimeter level in preclinical models. Additionally, we optimized the rapid incubation imaging method (RIIM) by shortening the procedure to less than 8 min, illustrating TTP-ICG's high performance in distinguishing malignant from normal tissues/fibroadenoma lesions as well as detecting metastatic lymph nodes in a cohort of 59 patients. Thus, this TROP2-targeting probe demonstrates its significance for fluorescence imaging-guided surgery with dual applicability in EBC, providing translational potential for further clinical decision-making.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
TROP2-targeted NIR-II fluorescence imaging for visualizing surgical margins and metastatic sentinel lymph nodes in breast cancers. · full record | OpenQuestion